Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Painting a Rosy Picture, Beleaguered Elan Seeks To Leave Its Troubles Behind

This article was originally published in The Pink Sheet Daily

Executive Summary

Elan reveals a hidden sweetener in its J&J deal, which will enable it to bid for the half of Tysabri it doesn't already own in the event Biogen is bought.

You may also be interested in...



Deals Of The Week: Mylan/Agila, UCB/Biotie, Jazz/Concert…

Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.

Court Date for Biogen and Elan Set for Sept. 3

The partners, who are litigating over Tysabri, face off earlier than expected.

Court Date for Biogen and Elan Set for Sept. 3

The partners, who are litigating over Tysabri, face off earlier than expected.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069725

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel